endometrioid stromal sarcoma
endometrioid stromal sarcoma
Explore linked clinical trials. Standard reference: MONDO:00067452 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ph 2 Elacestrant in ER Positive Uterine Sarcomas | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Urogenital Diseases, Urogenital Neoplasms, endometrial stromal tumor, endometrioid stromal sarcoma, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, leiomyosarcoma of the corpus uteri, mixed neoplasm, neoplasm, neoplasm with perivascular epithelioid cell differentiation, sarcoma, uterine corpus adenosarcoma, uterine disorder | Recruiting | Phase 2 | 2026-05-22 | NCT07467772 | |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Malignant Peripheral Nerve Sheath Tumors, Neoplasms by Histologic Type, Neoplasms, Adipose Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Nerve Tissue, Urogenital Diseases, Urogenital Neoplasms, angiosarcoma, connective tissue neoplasm, desmoplastic small round cell tumor, endometrial stromal tumor, endometrioid stromal sarcoma, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, fibrosarcoma, histiocytoma, leiomyosarcoma, liposarcoma, mixed neoplasm, myomatous neoplasm, neoplasm, nerve sheath neoplasm, nervous system disorder, neurofibroma, neurofibrosarcoma, neuromuscular disease, peripheral nervous system disorder, peripheral nervous system neoplasm, pleomorphic rhabdomyosarcoma, sarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, uterine disorder, vascular cancer | Recruiting | Phase 2 | 2025-07-24 | NCT06277154 |